肝功能不全患者伏立康唑群体药代动力学、安全性与剂量优化:前瞻性观察研究
该前瞻性观察研究纳入51例肝功能不全患者共272个伏立康唑浓度,采用ROC曲线探索谷浓度与毒性的关系,非线性混合效应法分析药代动力学,并按总胆红素分层进行剂量模拟。结果显示伏立康唑谷浓度≤5.1 mg/L与不良事件发生率显著降低相关,清除率与TBIL和血小板计数显著相关,分布容积随体重增加,据此提出了基于TBIL分层的优化给药方案。
要点
- 伏立康唑谷浓度≤5.1 mg/L与不良事件发生率显著降低相关。
- 清除率与TBIL和血小板计数显著相关,分布容积随体重增加。
- TBIL<51 μmol/L者可予负荷400 mg q12h首日,维持100 mg q12h。
核心结论
- 肝功能不全患者应考虑更低剂量和更长给药间隔,基于TBIL的给药方案有助于达到伏立康唑治疗范围。
研究设计与样本
- 前瞻性观察研究,纳入51例肝功能不全患者,共272个伏立康唑浓度。
- 采用ROC曲线探索谷浓度与毒性关系,非线性混合效应法分析药代动力学数据,并按TBIL分层进行剂量模拟。
主要发现
- ROC曲线分析显示伏立康唑谷浓度≤5.1 mg/L与不良事件发生率显著降低相关。
- 采用一室模型(一级吸收和消除)描述数据,清除率、分布容积和口服生物利用度分别为0.88 L/h、148.8 L和88.4%。
- 伏立康唑清除率与TBIL和血小板计数显著相关,分布容积随体重增加。
关键数值与推荐
- TBIL-1(TBIL<51 μmol/L)患者:首日负荷剂量400 mg q12h,维持剂量100 mg q12h口服或静脉给药。
- TBIL-2(51 μmol/L≤TBIL<171 μmol/L)患者:负荷剂量200 mg q12h,维持剂量50 mg q12h口服或静脉给药。
- TBIL-3(TBIL≥171 μmol/L)患者:负荷剂量200 mg q12h,维持剂量50 mg每日一次口服或静脉给药。
临床怎么用
- 对肝功能不全患者应根据TBIL分层选择负荷和维持剂量,并考虑降低剂量、延长给药间隔。
- 用药期间可监测伏立康唑谷浓度,目标控制在≤5.1 mg/L以降低不良事件风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: Voriconazole is a broad-spectrum antifungal agent for the treatment of invasive fungal infections. There is limited information about the pharmacokinetics and appropriate dosage of voriconazole in patients with liver dysfunction. This study aimed to explore the relationship between voriconazole trough concentration (Ctrough ) and toxicity, identify the factors significantly associated with voriconazole pharmacokinetic parameters and propose an optimised voriconazole dosing regimen for patients with liver dysfunction. METHODS: The study prospectively enrolled 51 patients with 272 voriconazole concentrations. Receiver operating characteristic curves were used to explore the relationship between voriconazole Ctrough and toxicity. The pharmacokinetic data was analysed with nonlinear mixed-effects method. Dosing simulations stratified by total bilirubin (TBIL, TBIL-1: TBIL < 51 μmol/L; TBIL-2: 51 μmol/L ≤ TBIL < 171 μmol/L; TBIL-3: TBIL ≥ 171 μmol/L) were performed. RESULTS: Receiver operating characteristic curve analysis revealed that voriconazole Ctrough of ≤ 5.1 mg/L were associated with significantly lower the incidence of adverse events. A 1-compartment pharmacokinetic model with first-order absorption and elimination was used to describe the data. Population pharmacokinetic parameters of clearance, volume of distribution and oral bioavailability were 0.88 L/h, 148.8 L and 88.4%, respectively. Voriconazole clearance was significantly associated with TBIL and platelet count. The volume of distribution increased with body weight. Patients with TBIL-1 could be treated with a loading dose of 400 mg every 12 hours (q12h) for first day, followed by a maintenance dose of 100 mg q12h administered orally or intravenously. TBIL-2 and TBIL-3 patients could be treated with a loading dose of 200 mg q12h and maintenance doses of 50 mg q12h or 100 mg once daily and 50 mg once daily orally or intravenously, respectively. CONCLUSIONS: Lower doses and longer dosing intervals should be considered for patients with liver dysfunction. TBIL-based dosing regimens provide a practical strategy for achieving voriconazole therapeutic range and therefore maximizing treatment outcomes.
引用
- Tang D, Yan M, Song BL, et al. Population pharmacokinetics, safety and dosing optimization of voriconazole in patients with liver dysfunction: A prospective observational study. Br J Clin Pharmacol. 2020. PMID: 33010043. doi:10.1111/bcp.14578
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。